Quantcast
Channel: Chicago Headlines on One News Page [United States]
Viewing all 46657 articles
Browse latest View live

NCSBN Makes Special Contribution to FNSNA

$
0
0
CHICAGO, April 05, 2018 (GLOBE NEWSWIRE) -- In honor of its 40^th anniversary this year, the National Council of State Boards of Nursing, Inc. (NCSBN^®), is making a special donation of $140,000 to the Foundation of the National Student Nurses Association (FNSNA). The check was presented to FNSNA by NCSBN Board of Directors President Katherine Thomas, MN, RN, FAAN, executive director, Texas Board of Nursing, during National Student Nurses’ Association’s Annual Convention in Nashville, Tenn. April 4-8, 2018.“NCSBN is celebrating its anniversary year by not only reflecting on its many past accomplishments but by investing in the future of the nursing workforce, which is why we are delighted to be able to make this contribution to provide scholarships to qualified undergraduate nursing students,” states Thomas.

NCSBN is a gold level sponsor of the “Forever Nursing... The Endowment Campaign for the FNSNA” and is a long-term supporter of the foundation and its mission.

FNSNA President Carol Toussie Weingarten, PhD, RN, commented, “NCSBN’s awesome contribution again shows the deep commitment to nursing students. We are truly grateful for their continued support to the future of the nursing profession!”

*About FNSNA*

FNSNA was created in 1969 and honors Frances Tompkins, the first executive director of the National Student Nurses' Association. Organized exclusively for charitable and educational purposes, the Foundation awards scholarships to qualified nursing students annually. More than $4.5 million dollars in scholarships to undergraduate nursing students, and over $3.9 million in Promise of Nursing Undergraduate Scholarships have been awarded. 

*About NCSBN*

NCSBN marks its 40th anniversary milestone in 2018 with the inspiring theme of “Regulatory Excellence Surging Toward the Future.” Founded March 15, 1978, as an independent not-for-profit organization, NCSBN was initially created to lessen the burdens of state governments and bring together boards of nursing (BONs) to act and counsel together on matters of common interest. It has evolved into one of the leading voices of regulation across the world.

NCSBN’s membership is comprised of the BONs in the 50 states, the District of Columbia, and four U.S. territories — American Samoa, Guam, Northern Mariana Islands and the Virgin Islands. There are also 30 associate members that are either nursing regulatory bodies or empowered regulatory authorities from other countries or territories.

NCSBN Member Boards protect the public by ensuring that safe and competent nursing care is provided by licensed nurses. These BONs regulate more than 4.8 million licensed nurses.

Mission: NCSBN provides education, service and research through collaborative leadership to promote evidence-based regulatory excellence for patient safety and public protection.

The statements and opinions expressed are those of NCSBN and not the individual member state or territorial boards of nursing.

*Contact: Dawn M. Kappel*
Director, Marketing and Communications
312.525.3667 direct
312.279.1034 fax
dkappel@ncsbn.org  Reported by GlobeNewswire 31 minutes ago.

Kim Kardashian Couldn’t Stop Kids From Crying During 1st Family Photoshoot With Chicago

$
0
0
Like father like kids! Unlike their matriarch, Kim Kardashian, the rest of the West family is not down for the whole picture taking thing. On Wednesday, the selfie queen shared the first photo of her family since they welcomed their new addition, Chicago West, and let’s just say, the family photo, which was taken on Read More

The post Kim Kardashian Couldn’t Stop Kids From Crying During 1st Family Photoshoot With Chicago appeared first on OK! Magazine. Reported by OK! Magazine 3 minutes ago.

Nikolic helps Fire get 1st win of the season, 1-0 over Crew

$
0
0
BRIDGEVIEW, Ill. (AP) Nemanja Nikolic scored after pouncing on a defensive miscue in the 27th minute to help the Chicago Fire beat the Columbus Crew 1-0 on Saturday night. Reported by FOX Sports 15 hours ago.

Crew-Fire, Sums

$
0
0
First half_1, Chicago, Nikolic, 4, 27th minute.Second half_None.Goalies_Columbus, Zack Steffen; Chicago, Richard Sanchez.Yellow Cards_Kappelhof, Chicago, 6th; Artur, Columbus, 47th; Sanchez, Chicago, 90th; Nikolic, Chicago,... Reported by New Zealand Herald 14 hours ago.

National League

$
0
0
___L.A. Dodgers at San Francisco, ppd.Atlanta 8, Colorado 3Pittsburgh 14, Cincinnati 3Milwaukee 5, Chicago Cubs 4San Diego 4, Houston 1N.Y. Mets 3, Washington 2St. Louis 5, Arizona 3Chicago Cubs 5, Milwaukee 2Philadelphia... Reported by New Zealand Herald 9 hours ago.

Chicago man slashed woman's cheek and jaw at bus station

$
0
0
A Chicago man accused of slashing a middle-aged woman’s face with a knife last week was ordered held without bail Saturday. Reported by FOXNews.com 6 hours ago.

Under Trump, new transportation grants ditch bikes, walkways

$
0
0
WASHINGTON (AP) — Forget about bike-share stations in Chicago or pedestrian walkways in Oakland. That's so Obama-era.In the Trump administration, a popular $500 million transportation grant program is focused more on projects in... Reported by New Zealand Herald 5 hours ago.

As U.S. and China trade tariff barbs, others scoop up U.S. soybeans

$
0
0
CHICAGO (Reuters) - Escalating tensions between the United States and China have triggered a flurry of U.S. soybean purchases by European buyers, in one of the first signs that trade tariff threats lobbed between the world's top two economies are disrupting global commodity trade flows. Reported by Reuters 5 hours ago.

Doctors Plastic Surgery Welcomes Dr. Azizi in the Chicago Location

$
0
0
Specialist Dr. Azizi Offers Body Contouring, Breast Augmentation and The Newest Reconstruction Surgical Treatments in Chicago

CHICAGO (PRWEB) April 08, 2018

Doctors Plastic Surgery-Chicago is excited to announce that specialist Dr. Ramsen Azizi, MD has joined their team of highly-qualified, board-certified cosmetic surgeons. The Chicago location offers the most modern aesthetic treatments in a safe, state of the art facility with reasonable prices. Safe, natural-looking results that provide the look that each client is dreaming of is Dr. Azizi' priority.

Doctor Azizi is an expert in both facial and body plastic surgery, including body contouring and breast augmentation. He is also recognized for his avid dedication to the application of breakthrough techniques in burn care, breast reconstruction and revolutionary reconstruction techniques for patients who have previously undergone skin cancer surgery. Dr. Azizi is proud to join the other talented, big-city surgeons at Doctors Plastic Surgery in Chicago. Dr. Azizi is currently taking new patients.

Native Chicagoan Ramsen Azizi at Doctors Plastic Surgery-Chicago

Plastic Surgeon Ramsen Azizi, MD is proud to represent his hometown. He was born and raised in Chicago, and he completed his undergraduate degree in science, graduating cum laude from Chicago's Loyola University. The Chicagoan then continued on to earn his medical degree from the prestigious Chicago Medical School at Rosalind Franklin University of Health Sciences. Dr. Azizi started his medical career journey as a surgical resident at Chicago's Presence Saint Joseph Hospital and then later accepted a plastic surgery fellowship in Long Island, NY, at Nassau University Medical Center. Dr. Azizi's heart is Chicago strong, and he is proud to join the dedicated cosmetic surgical team serving at Doctors Plastic Surgery's state-of-the-art facility in Chicago.

Dr. Azizi's Passion For Aesthetic Medicine

Dr. Azizi has a pleasant bedside manner and readily assists his patients through each step of their journey. Dr. Azizi fondly acknowledges that his 25 years of experience in music performance and production has beautifully sharpened and shaped his artistry skills as a surgeon. Dr. Azizi's passion for aesthetic medicine emerges from the combustion of his unique talents, including his passionate love for science, his musical and artistic skills and his creativity and devotion to serving others.

Breaching Financial Barriers to Reach a Better You

Dr. Azizi is also passionate about providing affordable options for his patients and is thrilled that Doctors Plastic Surgery is dedicated to removing financial barriers that could otherwise restrict patients from achieving their goals. Visit HERE to learn about helpful ways to finance your surgery. Doctors Plastic Surgery patient coordinators are financing experts who work alongside each patient to help them connect with a program that fits their unique budget. It is Dr. Azizi's goal to help his patients remove financial obstacles so that everyone can afford to look their best and to feel good about themselves!

If you are would like to meet with Dr. Ramsen Azizi, MD at Doctors Plastic Surgery-Chicago to discuss reconstructive or aesthetic surgery, please contact the Chicago office at 312-313-2833, or schedule an appointment ONLINE for additional information. Dr. Azizi will be happy to help you correct or enhance areas on your person to achieve your absolute best appearance. Reported by PRWeb 4 hours ago.

Facebook, Google, Apple, and Amazon have too much power — so it's time for regulators to take on tech's titans (FB, AMZN, GOOGL, AAPL)

$
0
0
Facebook, Google, Apple, and Amazon have too much power — so it's time for regulators to take on tech's titans (FB, AMZN, GOOGL, AAPL)· *In the wake of the Cambridge Analytica scandal, Facebook has been facing scrutiny about its size and power. *
· *The company has indeed become immensely powerful, but so too have Google, Apple, and Amazon.*
· *Their power has numerous bad effects for consumers and society, including the destruction of whole industries and even slow national economic growth.*
· *But for decades regulators have been ignoring such consequences of the concentration of corporate wealth.*
· *It's long past time for US regulators start focusing on such problems — and to do something about them.*

--------------------In an extended interview with Facebook's Sheryl Sandberg last week, National Public Radio host Steve Inskeep asked if she and her fellow executives at the company had ever asked themselves whether the social networking giant they oversaw had become too powerful.

Sandberg, Facebook's chief operating officer, assured Inskeep that was something she and her colleague had in fact thought about. But she didn't exactly give an answer to that question.

So let me answer it for her: Yes, Facebook has become too powerful. Guess what, so too have Google, Amazon, Apple, and maybe a few other tech giants.

Their power is having negative effects in a wide range of areas. Facebook and Google's duopoly control of digital advertising industry is helping kill off much of the publishing industry. Facebook's unprecedented scale and the sheer amount of data it has on its users has allowed propaganda artists to influence national elections.

Meanwhile, Amazon's growing market dominance is undermining the traditional brick-and-mortar retail industry. Apple is siphoning off nearly all of the profits in the smartphone industry, hindering other companies' ability to innovate or compete.

More broadly, there's growing evidence that the outsized market dominance of a handful of giant US companies is the cause of the slow economic growth we've seen in recent years and the years' long stagnation in workers' wages.

It's long past time for government antitrust regulators to step in. Because the companies are distinct from each other and exercise their control in different ways, the actions regulators will have to take will vary. Regardless, we as a society need to get serious about these companies' power — and constrain it.

*Regulators have focused too much on consumer prices*

This problem has been a long time coming. Arguably it dates back to the early days of the Reagan Administration, when officials — under the influence of the pro-business, anti-regulatory Chicago school of economics — reinterpretted antitrust law.

Prior to that, regulators actively tried to prevent companies from concentrating their power, blocking mergers or barring them from particular lines of business and even, the case of AT&T or Standard Oil, moving to break them up.

But the Reagan administration took a different tack on antitrust law. They no longer viewed sheer size or power as a problem. Instead, they thought it could be beneficial, if a company used its market power and scale to reduce prices. Beginning with those officials, antitrust regulators in general only worried about corporate power when it led to increases in the consumer prices.

In recent years, though, some policy makers and economists have begun to realize that if you look at corporate power only through the lens of consumer prices, you miss out on lots of other bad effects of business concentration.

Google's dominance of the web-search market has no direct effect on consumer prices; we consumers get to use its service for free. But the lack of competition in search means that Google has enormous power over what we see and access on the internet, and critics have charged repeatedly that it's used that power to favor its own services.

Likewise, Facebook's dominance of the social-networking market doesn't affect the price consumers pay; like Google, it offers its service for free. But from the widespread dissemination of fake news to the leaking of profile data on likely more than a billion users, there are big problems related to Facebook's enormous size.

But the antiregulatory zeal of the Chicago School-influenced policy makers has led them to ignore even more obvious examples of monopoly power. For example, Facebook and Google combined account for more than 70% of the US digital advertising market and more than 80% of all the growth in that market. Together, they now account for more than 25% of the global market for advertising of all kinds.

In the past, that kind of concentration of power would have spurred regulators to intervene in the market. Instead, they've just let Facebook and Google continue to get bigger, including, in Facebook's case, by buying promising — and potentially threatening — startups such as tbh.

*Google has been given a pass for allegedly doing the same stuff that got Microsoft in trouble*

The antiregulatory fervor has also led US regulators to give a pass to what look to be even blatant violations of antitrust law. One of the foundational principles of US competition law is that while it's legal to have a monopoly, such companies are generally forbidden from trying to use that power to extend their dominance into another market. It's that principle that led to the government's antitrust case against Microsoft; the company was accused of trying to use its dominance in PC operating systems to thwart competition in the nascent market for web browsers.

Google is accused of doing the same thing. The company's Android software is in a similar position to Windows 20 years ago; Android is the dominant smartphone operating system. According to the European Commission — which does take monopoly power seriously — Google has required Android smartphone makers that want to be able to offer customers access to its Google Play app store or to its search app to include a whole suite of other Google apps. That's almost the exact same thing that Microsoft was accused of, yet unlike in that case, US regulators have done nothing to stop it.

That laissez-faire attitude may soon change. Some in the Republican party have long expressed reservations about Google's power. Many politicians on both sides of the aisle are raising questions about Facebook following revelations about its role in the 2016 election and, more recently, in the wake of the Cambridge Analytica scandal.

Meanwhile, President Trump and Bernie Sanders both have criticized Amazon. And the need to take on corporate power more generally has become a rallying cry among Democrats, especially amid new research about how the lack of competition is stymying economic growth and wages.

*Here's an action list for regulators*

But if US regulators do start to take corporate power more seriously, what should they do?

Here are some suggestions:

*Force the companies to break apart into smaller pieces.* Take Alphabet Inc. Its Google unit controls the markets for search, search advertising, mobile operating systems, and, through YouTube, the streaming of consumer-produced videos. Its Chrome business dominates the browser market and computers running the Chrome OS operating system dominate the education market. Google sister company Waymo has a leading position in self-driving cars.

Regulators intent on curbing Alphabet's power might easily conclude that not all of those businesses ought to be controlled by the same company. They might try to force Google to divest itself of YouTube or demand a separation of its search and mobile apps businesses. Similarly, they could force Facebook to give up Instagram and WhatsApp.

*
Block new acquisitions.* The tech giants ought to be barred from making purchases that make them bigger or further restrict competition. Regulators who were truly concerned about Facebook's dominance of the social networking market would never have given it a free pass to buy WhatsApp.

*Block schemes in which the companies try to extend their power to new areas.* Again, this is just fundamental to US antitrust law. You can't allow a company that dominates in one area to use that power to try to seize control of another one. In practice, that would mean taking a serious look at the licensing terms Google uses to promote its smartphone apps. It also might give regulators a way to take on Apple and the preferential treatment it gives on the iPhone to its own apps, such as the Safari browser, and its own services, including Apple Music.

*Force the giants to lower switching costs.* The tech giants don't want you to switch, and they spend a lot of their time trying to design their services so that you'll stick around — both because everything within them works together so well, but also because it would be just too painful to go elsewhere. Regulators ought to make companies to make it easier to go to the competition.

For example, it's literally impossible to change the default apps on the iPhone. If you want to use Chrome as your default browser or Outlook as your default mail app, you're out of luck. Regulators could insist that Apple give consumers the power to set their own defaults.

Or take Amazon. Arguably one of the reasons it's been so successful is because it knows so much about its consumers; it can predict what they will want and set its prices and inventory accordingly. It might make sense for regulators to force the company to allow consumers to be able to take their shopping data to rival stores.

*Force the giants to open up their systems.* One way to get more competition would be to require the tech giants to make their technology available to potential competitors. Sure, companies must be able to benefit from their intellectual property and their innovation — that's fundamental to a vibrant economy. But when a product becomes an essential utility, leaving it in the hands of a single player can stiffle innovation and run counter to the best interests of society.

In the case of Google, that might mean making its search algorithms public so that other companies can copy and modify them. In the case of Amazon, it might mean forcing it to share its anonymized insights on consumer purchase behavior. For Apple, it might mean forcing the company to allow other companies to build devices using iOS or macOS, either by licensing them to competitors or by eliminating the copyright protection on older versions of those operating systems to push them into the public domain.

I'm sure there are other ideas out there; this isn't meant to be an exhaustive list. Some of these ideas may not work or may not be allowed under current law. And you can be sure the tech giants will fight tooth-and-nail against any attempts to curb their power.

But that's precisely what the present moment requires. These companies are way too powerful, and it's long past time that we get them under control.

*SEE ALSO: Facebook drops a bombshell and says most of its 2 billion users may have had their personal data scraped*

Join the conversation about this story »

NOW WATCH: The best and worst features of the Samsung Galaxy S9 Reported by Business Insider 4 hours ago.

Kim Kardashian's Struggle-Filled Easter & More — This Week In Celebrity Twitpics & Instagrams!

$
0
0
Greetings from the West family! This week, Kim Kardashian shared pics from the KarJenner Easter celebration, including her first family pic with newborn Chicago West! So precious! But this wasn't the only buzzworthy moment featured on social media! Andy Cohen rode the F train, Kendall Jenner hung out with fellow model superstar Kaia Gerber, and Gwyneth Paltrow ate [...] Reported by Perez Hilton 3 hours ago.

National Basketball Association

$
0
0
x-clinched playoff spoty-clinched divisionz-clinched conference___Denver 134, L.A. Clippers 115Milwaukee 115, New York 102Brooklyn 124, Chicago 96New Orleans 126, Golden State 120Oklahoma City 108, Houston 102San... Reported by New Zealand Herald 3 hours ago.

Pharmaceutical giants are sidestepping US marijuana restrictions to research cannabis-based drugs

$
0
0
Pharmaceutical giants are sidestepping US marijuana restrictions to research cannabis-based drugs· *Federal policies restricting marijuana research have made it difficult to study marijuana and produce cannabis-based drugs — but that isn't stopping pharmaceutical companies from doing it.**
*
· *Some are researching and developing drugs made with marijuana compounds in labs just north of the border. Others are growing the raw materials for their products in South America.
*
· *Although only a single cannabis-based drug is currently approved for use in the US, others are likely on their way.*
· *Some will appear first in marijuana dispensaries in states where marijuana has been legalized; others will await approval from the US Food and Drug Administration (FDA). *

--------------------Getting marijuana-based drugs approved in America is no easy task.

According to the US Drug Enforcement Administration, cannabis has no medical use. Until two years ago, all domestic research on the drug had to rely on rotting samples from a single, well-secured weed facility at the University of Mississippi. Today, researchers who want to grow marijuana have to apply for a license in a convoluted process that can take years. Only a single cannabis-based drug has been approved by the Food and Drug Administration to date — and it contains CBD, a non-psychoactive compound in marijuana that is not responsible for its characteristic high.

But as researchers are only beginning to uncover, marijuana — with its roughly 400 compounds, each of which is potentially responsible for a distinct effect — has a wide variety of potential medical applications, from relieving pain and nausea to reducing the symptoms of rare diseases like childhood epilepsy. And these benefits are emerging just as scientists are uncovering huge downsides to traditional medications like opioids.

Some are lending their support to Canadian marijuana startups growing their products in countries like Colombia; others are applying for permits to import marijuana extracts like CBD and THC; still others are obtaining approval in Europe first and hoping that validation gives them an edge during the difficult FDA approval process.

*Cannabis startups are among a handful of 'resident' startups at the Johnson & Johnson incubator in Canada*

At Johnson & Johnson's JLabs in Toronto, scientists and entrepreneurs follow a gleaming steel road towards shared workspaces separated only by clear glass walls. Pops of bright blue honeycomb print and creative lighting imbue the center with a sense that change is right around the corner.

It was here, roughly a year ago, that the pharmaceutical giant welcomed the first marijuana startup into its JLabs Innovation network, an ecosystem designed to give budding companies access to the resources and leadership they need to get off the ground. JLabs accepted a second cannabis company, Vapium Medical, as a resident about three months later.

The first was Avicanna, a Toronto-based biotech company focused on medical cannabis.

As part of the JLabs ecosystem, Avicanna gets access to lab space, a Johnson & Johnson mentor, and the recognition they need to recruit top-notch scientists and researchers. In exchange, Johnson & Johnson get a chance to work with an innovative company and invest if and when they see fit.

"Partnering with JLabs allowed us to obtain a lot of credibility," Aras Azadian, Avicanna's CEO, told Business Insider. "It's also a great atmosphere to work in and to bring others in."

Before getting accepted as a JLabs resident (after applying for the third time), Avicanna was a fledgling startup, Azadian said. But that changed when the company joined JLabs.

In just over a year, the company went from a staff of five to 17 in Canada and 30 in Colombia, where the company grows and harvests the marijuana that goes into its products — which thus far include a series of patches, creams, and sprays that will be sold under the Pura Elements brand. Azadian said he expects a selection of those products to be available in dispensaries in California, where marijuana is legal, by the end of this year.

Azadian says that while Johnson & Johnson isn't yet invested financially in Avicanna, just being in the space significantly raises the chances that the pharmaceutical giant might eventually take that leap.

"Since we’re part of their ecosystem it’s much more convenient to cooperate and collaborate — a lot more so than to start working with new company," Azadian said. "I think we’ve positioned ourselves well to be a good fit for them."

Avicanna’s initial product lineup will go to US dispensaries in states where marijuana is legal, like California.

But Azadian is hopeful that the company's research with scientists at the University of Toronto, including tests in cells and mice and eventual clinical trials in humans, will bolster their next line of products, which are geared towards treating medical conditions like eczema. Avicanna also hopes to eventually launch sustained-release capsule formulations aimed at pain relief.

"I think with our approach — strictly looking at this from a medical perspective with a team of some of the best scientists on board — I'm excited to see where this goes," Azadian said.

*Other pharma companies are looking to study cannabis by importing extracts*

Instead of going the incubator route, several small pharmaceutical companies are applying for federal permits to import cannabis extracts like CBD and THC.

Those companies include Virginia-based research group Sanyal Biotechnology, a contract-based drugmaker that focuses on liver diseases and was spun out of Virginia Commonwealth University in 2015; and Noramco, a Delaware-based drugmaker that focuses on medications used to treat illnesses including ADHD and addiction as well as pain.

Both companies filed reports in March with the DEA's federal register to import cannabis extracts; Noramco also applied for a permit to import whole plant material.

Sanyal's decision to import cannabis extracts comes from a recent partnership with Ontario-based cannabis drug company Revive Therapeutics. Last year, Revive reached out to Sanyal to inquire about testing CBD for its potential effects on autoimmune hepatitis, a chronic disease in which the body's immune system attacks the liver.

Around that time, Sanyal applied for a permit with the DEA to study CBD; but the company has yet to be cleared to import the extracts.

Rebecca Caffrey, Sanyal's CEO, told Business Insider that while she understands the need for approval, the application and permitting process has seemed excessive at times. If they don't recieve the required permits by this summer, Sanyal may need to refer Revive back to Canada where another lab will take over the research.

"We've just been going through all these hoops," Caffrey said. "I understand why they have to have these restrictions, but it does make it hard to do business."

*Only one cannabis-based drug has the FDA's stamp of approval*

So far, only one cannabis-based drug has been approved via the traditional drug-approval route, which involves working closely with multiple regulatory agencies including the DEA and FDA.

That drug, known by its generic name dronabinol, is designed to treat some of the negative side-effects of chemotherapy and AIDS, such as nausea, loss of appetite, and weight loss. It is made using lab-produced versions of THC, the main psychoactive ingredient in marijuana.

Chicago-based Abbott Pharmaceuticals spinoff AbbVie got approval for its dronabinol formulation, which is in pill form and called Marinol, by making the case that it offered advances where no other adequate therapies existed. Arizona-based drug company Insys Therapeutics also recently received approval for a liquid version of dronabinol that treats the same conditions.

The next company to secure FDA approval for a cannabis-derived drug could be the UK-based pharmaceutical company GW Pharmaceuticals, which recently secured approval for clinical trials in just four US states via its American subsidiary Greenwich Biosciences. In December, the company secured "priority review" for its epilepsy drug, Epidiolex, which could fast-track the typically multi-year approval process.

Still, the road ahead for GW is long — the company expects approval only as early as the summer of 2018. Notably, the drug contains only CBD, so there is no chance of getting users high.

"There's certainly demand for these products," Avicanna's Azadian said, "but we're still dealing with a strictly stigmatized industry."

*SEE ALSO: Ketamine could be the new drug for depression that researchers have been looking for*

Join the conversation about this story »

NOW WATCH: Here's what happens in your body when you swallow gum Reported by Business Insider 2 hours ago.

American League

$
0
0
___N.Y. Yankees 8, Baltimore 3Boston 10, Tampa Bay 3Detroit 6, Chicago White Sox 1Seattle 11, Minnesota 4Kansas City 1, Cleveland 0Houston 1, San Diego 0, 10 inningsTexas 5, Toronto 1Oakland 7, L.A. Angels 3Seattle... Reported by New Zealand Herald 2 hours ago.

The NHP Foundation Appoints Glynna Christian Trustee

$
0
0
Orrick Global Technology Transactions Co-Head joins organization

NEW YORK (PRWEB) April 11, 2018

The NHP Foundation (NHPF) is pleased to announce that it has appointed Glynna Christian to the NHPF Board of Trustees.

As Co-Head of the Global Technology Transactions practice at Orrick, Glynna brings to the Board of Trustees a wealth of commercial and legal knowledge in M&A, financings, public offerings, joint ventures and other strategic transactions.

"In addition to experience advising clients in corporate and commercial deals across virtually all operational and strategic areas of their business, Glynna’s expertise in launching new technology and digital products, including blockchain and Artificial Intelligence (AI) bring an exciting new dimension to the affordable housing space," said NHPF CEO Richard F. Burns. “We know Glynna will be a great addition to NHPF’s future endeavors.”

In her role at Orrick, Glynna advises both emerging and established companies, in deal-making across virtually all operational and strategic areas of their businesses. She has more than 20 years' experience counseling clients on emerging and transformative technology, communications, media and data transactions that are strategic to her clients’ businesses.

Glynna earned her J.D. from the University Of Memphis Cecil C. Humphreys School Of Law, 1994, cum laude, and her B.A. from the University of North Texas, 1990, cum laude. An active and sought-out thought leader, Glynna has lectured for a variety of professional organizations and written numerous articles on technology and digital transactions. She also serves on the board of directors of Legal Momentum and the Children’s Arts Guild.

About The NHP Foundation
Headquartered in New York City with offices in Washington, DC, and Chicago, IL, The NHP Foundation was launched on January 30, 1989, as a publicly supported 501(c)(3) not-for-profit real estate corporation. NHPF is dedicated to preserving and creating sustainable, service-enriched multifamily housing that is both affordable to low and moderate income families and seniors, and beneficial to their communities. NHPF also provides a robust resident services program to more than 28,000 community residents. Through partnerships with major financial institutions, the public sector, faith-based initiatives, and other not-for-profit organizations, NHPF has preserved 81 properties, totaling 14,259 units in 18 states and the District of Columbia. Today, NHPF’s portfolio includes 40 properties, totaling 6,801 apartment units, in 18 states and the District of Columbia. For more information on The NHP Foundation, please visit http://www.nhpfoundation.org. Reported by PRWeb 2 hours ago.

NAPA Executive Leader, Peter Doerner Speaking on “The Evolution of ASCs and Physician-Hospital Joint Ventures” at Becker's Hospital Review 9th Annual Meeting

$
0
0
MELVILLE, N.Y., April 11, 2018 (GLOBE NEWSWIRE) -- North American Partners in Anesthesia (NAPA), one of the largest single-specialty anesthesia and perioperative management companies in the United States, announced today that Peter Doerner, Executive Vice President & Chief Development Officer, will serve on an educational panel at Becker’s Hospital Review 9^th Annual Meeting. The event will take place April 11 – 14, 2018 at the Hyatt Regency in Chicago, IL.  The “Evolution of ASCs and Physician-Hospital Joint Ventures” panel will be held on Thursday, April 12, from 3:50 – 4:30 PM.  The panel will answer questions about benefits, challenges and industry trends in joint ventures, including how physician-hospital ASC joint ventures have evolved, how to best set-up and manage these partnerships and the future of the joint venture model. The other panelists include Don Barbo, CPA/ABV, Managing Director, VMG Health; Dawn Knight, CEO/Administrator, Center for Minimally Invasive Surgery; Viveka Rydell-Anderson, Esq., CEO, PDI Surgery Center; and moderator Megan Wood, Assistant Managing Editor, Becker’s Healthcare.

According to Mr. Doerner,* “*It’s an honor to join this distinguished panel as we delve into the relationships between ASCs, Physicians, and Hospitals as they work together to execute joint venture models that create a win win for all. Our organization has had the privilege of working with these stakeholders for the past three decades. It will be interesting to share lessons learned and best practices observed with my colleagues on the panel and in the audience.”

Peter Doerner is a proven senior executive with over 30 years of Healthcare leadership experience in hospitals and other healthcare facilities. He has created significant solutions for healthcare organizations focused on continuous operational, fiscal, and clinical improvement. Mr. Doerner currently leads a talented team of professionals focused on growing the NAPA-related businesses in a nationwide expansion with a focus on delivering excellence to patients, surgeons, and administrators.

Becker’s Hospital Review conference brings together hospital business and strategy leaders to discuss how to improve hospitals and their bottom lines in these challenging but opportunity-filled times. 

*About North American Partners in Anesthesia
*As a clinician-led organization, North American Partners in Anesthesia (NAPA) is redefining healthcare, delivering unsurpassed excellence to its partners and patients every day. In three decades, NAPA has grown to become one of the nation’s leading single-specialty anesthesia and perioperative management companies, serving more than one million patients annual in more than 260 healthcare locations throughout the Northeast, Mid-Atlantic, Midwest, and Southeast. For more information, please visit www.napaanesthesia.com.

*Media Contact:
*Heather Dall’Aste
North American Partners in Anesthesia
P: (516) 370-3638
E: hdallaste@napaanesthesia.com

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/d7521ff3-625e-471f-a07e-4a349cdf5ae3 Reported by GlobeNewswire 2 hours ago.

Belmont Village Aliso Viejo Tops Out — Major Construction Milestone Achieved

$
0
0
First Belmont Senior Living community in Orange County to provide Assisted Living and Memory Care

Houston, Texas, April 11, 2018 (GLOBE NEWSWIRE) -- Belmont Village Senior Living has reached a construction milestone with the “topping out” of its twenty-ninth community located at 300 Freedom Lane in Aliso Viejo. Contractor W.E. O’Neil has completed the concrete structure of the three-story building with the final roof placement. The milestone was celebrated on Thursday, March 29, 2018 with an on-site barbeque for subcontractors and special guests.

Belmont Village was founded in 1997 as an integrated developer, owner and operator of high-end seniors housing. In the 20 years since, the company has developed and still operates 27 senior living communities in seven states and Mexico City. The most recent community opened March 24, 2018 in Calabasas.

“Building to high standards for life safety and quality has been the hallmark of our company from the beginning,” said Patricia Will, Belmont Village Founder and CEO. “In W.E. O’Neil, we have found a partner who has a reputation for quality construction and a deep understanding of our unique building requirements. We’ve built several communities together now, creating a very consistent product across markets.” 

In addition to the Aliso Viejo site, Belmont Village currently has four projects under construction in California, Chicago, Texas and Florida. This will be the first community Belmont Village has built in Orange County. Each Belmont Village is built to purpose and licensed throughout the building to provide a blended model of care that offers flexibility for residents if care needs change and allows couples with varying health or cognitive needs to continue to stay together.

“It is gratifying to see new residents move into our buildings, enjoy the variety of community spaces and experience the health, wellness and connectivity that they need to maintain purposeful lives,” said Will. “We take care of all the details such as higher construction standards, licensure of our buildings, research to support our programs and gold-standard training to contribute to the success of each community”

The 123,877-square-foot Mediterranean-style property is scheduled to open in January, 2019 with 148 residences featuring one-bedroom and studio apartments for Assisted Living and Memory Care. The architectural firm of Van Tilburg, Banvard & Soderbergh designed the building. Features include a professionally managed fitness center, heated saltwater pool, full service salon and exterior courtyards with outdoor dining patios and gardens by landscape architect is Ridge Landscape Architects.

Belmont Village is a leading senior living provider known for distinctive design, high standards for life safety, and reputation for quality care and innovative, award-winning programs. Residents enjoy chef prepared meals, housekeeping, concierge and transportation services, a full daily calendar of social and enrichment activities, and support from a well-trained staff, including licensed nurses on-site 24/7. For more information, call 949-643-1050 or visit www.belmontvillage.com. ###

*Attachment*

· 20180329-Belmont_aliso_Viejo-Topping-Out-37

CONTACT: Amy Self
Belmont Village Senior Living
7134631730
aself@belmontvillage.com

Lorena Grimes
Belmont Village Senior Living
7134631786
lgrimes@belmontvillage.com Reported by GlobeNewswire 2 hours ago.

Officer fired after dragging passenger sues United, Chicago

$
0
0
CHICAGO (AP) — An aviation security officer fired after forcibly dragging a passenger from a plane last year has filed a lawsuit against United Airlines and the city of Chicago.James Long was one of the officers called to a plane... Reported by New Zealand Herald 2 hours ago.

Watch Sister Jean throw a ceremonial first pitch at the Cubs' home opener

$
0
0
Sister Jean did just fine on the diamond, too.

The popular 98-year-old chaplain of the Loyola-Chicago basketball team that reached the Final Four switched sports Tuesday, throwing out a first ball before the Cubs' home opener.

Sister Jean Dolores Schmidt drew a big cheer at Wrigley Field when she... Reported by L.A. Times 2 hours ago.

Billionaire donates $10 million to fight crime in Chicago

$
0
0
CHICAGO (AP) — Billionaire hedge fund manager and philanthropist Ken Griffin is throwing $10 million at Chicago’s effort to fight violent crime. In a news release, Mayor Rahm Emanuel announced that the money will support the collaboration between the University of Chicago Crime lab and the police department to set up and operate Strategic Decision […] Reported by Seattle Times 59 minutes ago.
Viewing all 46657 articles
Browse latest View live




Latest Images